Description: Prime Medicine is a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address the widest spectrum of diseases. The company is deploying Prime Editing technology, a versatile, precise, efficient and broad gene editing technology, which is designed to make only the right edit at the right position within a gene. With the theoretical potential to repair approximately 90 percent of known disease-causing genetic mutations across many organs and cell types, medicines based on Prime Editing, if approved, could offer a one-time curative genetic therapeutic option to a broad set of patients.
Home Page: www.primemedicine.com
PRME Technical Analysis
21 Erie Street
Cambridge,
MA
02139
United States
Phone:
617-564-0013
Officers
| Name | Title |
|---|---|
| Dr. Keith Michael Gottesdiener M.D. | Pres, CEO, Sec. & Director |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer |
| Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder, Sr. Scientist II, Head of Prime Editing Platform & Head of Platform Devel. |
| Dr. David R. Liu Ph.D. | Co-Founder & Chair of Scientific Advisory Board |
| Ms. Carman Alenson CPA, M.B.A. | Chief Accounting Officer & Interim CFO |
| Dr. Meredith Goldwasser | Sr. VP of Strategy & Corp. Operations and Head of Strategy & Corp. Operations |
| Dr. Karen Brown J.D., Ph.D. | Sr. VP of Intellectual Property & Legal Affairs |
| Ms. Niamh Alix | Chief HR Officer |
| Mr. Richard Brudnick | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-10-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 150 |